COG to present at Mello 2026

Cambridge, UK, 1 June 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces that the Company will be presenting at the Mello 2026 investor event.

Rob Baker, CEO, will present on Wednesday, 3 June 2026, at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY. Rob will be joined by other members of the senior leadership team to take investors questions during the day.

The presentation follows a series of recent positive news events including:

• FY 2025 financial results showing a 73% increase in new sales orders to £12.8m and a 21% increase in the order book £16.5m;
• The launch of the professional healthcare and consumer health business with agreements with a major European healthcare provider, and an agreement with venture backed Ivory for the Indian market; and
• The announcement of a 45,000 participant IRB-approved Brain Health Study with the world's leading smart ring maker OURA.

Rob's presentation titled "Making Brain Health Measurable At Scale" addresses how Cambridge Cognition has built on 30 years of neuroscience and technology development, with its digital touch-screen and voice-based cognitive assessments. These have been used for decades supporting academic researchers and clinical drug development and are now being taken into the professional healthcare and consumer health & wellness market. These markets require highly scalable, reliable, consistent and accurate information delivered without administrator bias in near real time to users.